A polyvalent virosomal influenza vaccine induces broad cellular and humoral immunity in pigs.
Cellular immunity
Humoral immunity
Influenza A virus
Swine
Virosomal vaccine
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
16 08 2023
16 08 2023
Historique:
received:
17
05
2023
accepted:
06
08
2023
medline:
18
8
2023
pubmed:
17
8
2023
entrez:
16
8
2023
Statut:
epublish
Résumé
Influenza A virus (IAV) is endemic in pigs globally and co-circulation of genetically and antigenically diverse virus lineages of subtypes H1N1, H1N2 and H3N2 is a challenge for the development of effective vaccines. Virosomes are virus-like particles that mimic virus infection and have proven to be a successful vaccine platform against several animal and human viruses. This study evaluated the immunogenicity of a virosome-based influenza vaccine containing the surface glycoproteins of H1N1 pandemic, H1N2 and H3N2 in pigs. A robust humoral and cellular immune response was induced against the three IAV subtypes in pigs after two vaccine doses. The influenza virosome vaccine elicited hemagglutinin-specific antibodies and virus-neutralizing activity. Furthermore, it induced a significant maturation of macrophages, and proliferation of B lymphocytes, effector and central memory CD4 This virosome platform allows flexibility to adjust the vaccine content to reflect the diversity of circulating IAVs in swine in Brazil. The vaccination of pigs may reduce the impact of the disease on swine production and the risk of swine-to-human transmission.
Sections du résumé
BACKGROUND
Influenza A virus (IAV) is endemic in pigs globally and co-circulation of genetically and antigenically diverse virus lineages of subtypes H1N1, H1N2 and H3N2 is a challenge for the development of effective vaccines. Virosomes are virus-like particles that mimic virus infection and have proven to be a successful vaccine platform against several animal and human viruses.
METHODS
This study evaluated the immunogenicity of a virosome-based influenza vaccine containing the surface glycoproteins of H1N1 pandemic, H1N2 and H3N2 in pigs.
RESULTS
A robust humoral and cellular immune response was induced against the three IAV subtypes in pigs after two vaccine doses. The influenza virosome vaccine elicited hemagglutinin-specific antibodies and virus-neutralizing activity. Furthermore, it induced a significant maturation of macrophages, and proliferation of B lymphocytes, effector and central memory CD4
CONCLUSIONS
This virosome platform allows flexibility to adjust the vaccine content to reflect the diversity of circulating IAVs in swine in Brazil. The vaccination of pigs may reduce the impact of the disease on swine production and the risk of swine-to-human transmission.
Identifiants
pubmed: 37587490
doi: 10.1186/s12985-023-02153-5
pii: 10.1186/s12985-023-02153-5
pmc: PMC10428566
doi:
Substances chimiques
Influenza Vaccines
0
Vaccines, Combined
0
Virosomes
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
181Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
J Virol. 2015 Apr;89(7):3763-75
pubmed: 25609810
J Clin Microbiol. 2001 Mar;39(3):924-9
pubmed: 11230405
Eur J Pharm Biopharm. 2015 Aug;94:251-63
pubmed: 26047796
Vaccine. 2012 Jan 5;30(2):280-8
pubmed: 22067263
Clin Vaccine Immunol. 2012 Nov;19(11):1722-9
pubmed: 22933397
Sci Rep. 2022 Mar 10;12(1):3884
pubmed: 35273217
Front Immunol. 2021 Nov 05;12:747574
pubmed: 34804030
Front Vet Sci. 2020 Sep 22;7:647
pubmed: 33195504
Methods Mol Biol. 2020;2123:281-294
pubmed: 32170695
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4481-4488
pubmed: 30787194
Viral Immunol. 2000;13(4):511-20
pubmed: 11192298
Emerg Infect Dis. 2006 Jan;12(1):48-54
pubmed: 16494717
Viral Immunol. 2006 Summer;19(3):373-82
pubmed: 16987057
Vet Microbiol. 2001 Mar 2;79(1):47-62
pubmed: 11230928
Nat Med. 2012 Jan 29;18(2):274-80
pubmed: 22286307
J Appl Microbiol. 2010 Apr;108(4):1323-31
pubmed: 19778350
Arch Virol. 2015 Jan;160(1):29-38
pubmed: 25209152
Transbound Emerg Dis. 2022 Mar;69(2):903-907
pubmed: 33590723
Vaccine. 2016 Jul 12;34(32):3634-40
pubmed: 27211039
Methods Mol Biol. 2014;1161:295-301
pubmed: 24899438
Methods Mol Biol. 2014;1161:313-24
pubmed: 24899440
Emerg Infect Dis. 2017 Jan;23(1):152-154
pubmed: 27983507
Expert Rev Vaccines. 2018 Sep;17(9):785-795
pubmed: 30145912
Vaccine. 2009 Jul 16;27(33):4381-7
pubmed: 19450630
Vaccine. 2007 Oct 10;25(41):7065-74
pubmed: 17766014
Front Microbiol. 2023 Aug 08;14:1243567
pubmed: 37614592
Cold Spring Harb Perspect Med. 2021 Mar 1;11(3):
pubmed: 31988203
Sci Rep. 2022 Sep 17;12(1):15630
pubmed: 36115917
Vet Microbiol. 2017 Jul;206:35-44
pubmed: 27923501
Curr Top Microbiol Immunol. 2013;370:173-200
pubmed: 22976350
Res Vet Sci. 2018 Jun;118:199-246
pubmed: 29518710
J Virol. 2017 Jan 31;91(4):
pubmed: 27928015
Vet Microbiol. 2016 Aug 15;191:35-43
pubmed: 27374905
Viruses. 2023 Feb 19;15(2):
pubmed: 36851790
J Immunol. 2011 Apr 1;186(7):3823-9
pubmed: 21422252
Nat Med. 2013 Oct;19(10):1305-12
pubmed: 24056771
Vet Microbiol. 2004 Aug 19;102(1-2):55-65
pubmed: 15288927
Front Immunol. 2018 Apr 09;9:678
pubmed: 29686673
Vaccine. 2003 Mar 28;21(13-14):1375-81
pubmed: 12615433
Influenza Other Respir Viruses. 2013 Sep;7(5):783-90
pubmed: 23280098
Vaccine. 2005 Jul 8;23 Suppl 1:S26-38
pubmed: 16026906
Vaccine. 2011 Feb 11;29(8):1657-65
pubmed: 21195078
Vaccine. 2004 Oct 22;22(31-32):4390-6
pubmed: 15474733
Vet Pathol. 2003 Sep;40(5):521-9
pubmed: 12949409
Vet Immunol Immunopathol. 2006 Apr 15;110(3-4):279-92
pubmed: 16325923
Lancet. 1994 Jul 16;344(8916):160-3
pubmed: 7912766
Immunity. 2013 Apr 18;38(4):805-17
pubmed: 23583644
Biomed Res Int. 2021 Jan 29;2021:8879277
pubmed: 33575353
Methods Mol Biol. 2020;2123:295-310
pubmed: 32170696
Nanomedicine. 2019 Feb;16:226-235
pubmed: 30611772
Nat Rev Immunol. 2019 Jun;19(6):383-397
pubmed: 30837674
Emerg Infect Dis. 2015 Aug;21(8):1339-47
pubmed: 26196759
Methods Mol Biol. 2020;2123:345-351
pubmed: 32170700
Pediatr Infect Dis J. 2007 Aug;26(8):705-10
pubmed: 17848882
Virol J. 2023 Aug 21;20(1):187
pubmed: 37605141
Avian Dis. 2004 Apr-Jun;48(2):332-43
pubmed: 15283420
J Vet Diagn Invest. 2020 Mar;32(2):301-311
pubmed: 32100644
Proc Natl Acad Sci U S A. 2012 May 1;109(18):7037-42
pubmed: 22509047
Immunol Lett. 2009 Feb 21;122(2):118-21
pubmed: 19100779